Ltr Pharma (ASX:LTP)
ASX announcement history & article coverage
Transparent by design.
Announcments by Ltr Pharma (ASX:LTP) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification regarding unquoted securities - LTP
OROFLOW Clinical Study Receives Ethics Approval
LTR Pharma's OROFLOW® Intranasal Spray Approved for Clinical Study in Oesophageal Motility Disorders
Response to ASX Aware Letter
LTR Pharma confirms timely disclosure of binding US ROXUS agreement following ASX query
LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
LTR Pharma secures exclusive US pharmacy partner for ROXUS® ahead of commercial launch
LTR Secures First U.S. Commercial Agreement for ROXUS
LTR Pharma signs binding U.S. telehealth deal with Shed Holdings for ROXUS commercialisation
Investor Presentation
LTR Pharma advances rapid-onset intranasal ED therapy SPONTAN with strong clinical data, strategic partnerships, and $24.1M cash
SPONTAN Phase II data show rapid onset, support FDA pathway
Trading Halt
Quarterly Activities/Appendix 4C Cash Flow Report
LTR Pharma completes SPONTAN Phase II recruitment; interim data due Q2 2026; ROXUS US commercial talks progress